(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.

The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...

Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...

Since 2013, diagnoses of multiple sclerosis (MS) in Finland take less time after symptom onset and treatments follow the ...

Emasan AG is offering around 26.5M shares in Swiss Novartis (NVS) through Goldman Sachs, potentially raising $3B, Pablo Mayo Cerqueiro of ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Corundum Systems Biology (CSB), a leading investment company dedicated to advancing life-changing systems biology solutions for human health and well-being, today announced the appointment of two ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

The site is expected to accelerate Amgen’s digital capabilities through artificial intelligence and data science to further ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund ...

Objectives Tendinopathy is a frequent clinical problem and represents an extraordinary health economic and socioeconomic burden with high unmet medical needs. Recent clinical evidence suggests ...